Mesenchymal stem cells-based drug delivery systems for diabetic foot ulcer:A review
作者机构：Department of EndocrinologyPeople’s Hospital of Chongqing Liangjiang New AreaChongqing 400030China Department of EndocrinologyThe Second Affiliated Hospital of The Chongqing Medical UniversityChongqing 400030China Department of EndocrinologyDazu Hospital of Chongqing Medical UniversityThe People’s Hospital of DazuChongqing 406230China
出 版 物：《World Journal of Diabetes》 (世界糖尿病杂志（英文版）（电子版）)
年 卷 期：2023年第14卷第11期
页 面：1585-1602页
核心收录：
基 金：Supported by Science and Health Joint Medical Research Project of Chongqing,No.2022MSXM133 Natural Science Foundation of Chongqing,No.CSTB2022NSCQ-MSX1522,No.CSTB2023NSCQ-MSX0246,No.CSTB2022NSCQ-MSX1271 The First Batch of Key Disciplines on Public Health in Chongqing and Science Health Joint Project of Dazu District Science and Technology Bureau,No.DZKJ,2022CCC1001.
主 题：Diabetic foot ulcer Mesenchymal stem cells Drug delivery systems Diabetes Wound healing
摘 要：The complication of diabetes,which is known as diabetic foot ulcer(DFU),is a significant concern due to its association with high rates of disability and mortality.It not only severely affects patients’quality of life,but also imposes a substantial burden on the healthcare system.In spite of efforts made in clinical practice,treating DFU remains a challenging task.While mesenchymal stem cell(MSC)therapy has been extensively studied in treating DFU,the current efficacy of DFU healing using this method is still inadequate.However,in recent years,several MSCs-based drug delivery systems have emerged,which have shown to increase the efficacy of MSC therapy,especially in treating DFU.This review summarized the application of diverse MSCs-based drug delivery systems in treating DFU and suggested potential prospects for the future research.
维普期刊数据库